SEARCH

SEARCH BY CITATION

Keywords:

  • blastic plasmacytic dendritic cell neoplasm;
  • flow cytometry;
  • acute leukemia;
  • CD123;
  • CD4+/CD56+

CASE HISTORY

  1. Top of page
  2. CASE HISTORY
  3. FLOW CYTOMETRIC STUDIES
  4. DISCUSSION
  5. LITERATURE CITED
  6. Supporting Information

The patient is an 81-year-old gentleman who was referred to the hematology/oncology service for worsening fatigue and skin lesions. His past medical history is significant for myelodysplastic syndrome diagnosed 5 months ago. He was symptomatically treated and followed a relatively stable course until approximately 1 month ago. At that time, he noticed multiple skin lesions over his trunk and legs, and also became increasingly fatigued with exertional dyspnea, finding himself short of breath after climbing one flight of stairs. Laboratory data were significant for 30% circulating blasts, neutropenia (ANC = 0.96/mm3), macrocytic anemia (Hgb 7.7 g/dL, MCV 109.6), and thrombocytopenia (52 × 109/L). A bone marrow biopsy was performed for further evaluation (Fig. 1).

image

Figure 1. Wright-Giemsa-stained bone marrow aspirate smear demonstrating numerous blasts. Note the cytoplasmic “tails” (500×).

Download figure to PowerPoint

FLOW CYTOMETRIC STUDIES

  1. Top of page
  2. CASE HISTORY
  3. FLOW CYTOMETRIC STUDIES
  4. DISCUSSION
  5. LITERATURE CITED
  6. Supporting Information

Flow cytometry was performed for CD7, CD13, CD33, CD19, CD56, CD123, CD45, CD56, CD14, CD34, CD15, CD117, HLA-DR, CD16/57, CD4, CD8, CD2, CD16, CD13, CD11b, CD36, CD64, TdT, MPO. List mode files and example analysis for the following tubes are available as Supporting Information: CD7-FITC, CD123-PE, CD45-PerCP-Cy5, CD56-APC; CD14-FITC, CD13/33-PE, CD45-PerCP-Cy5.5, CD34-APC; CD15-FITC, CD33-PE, CD117-PerCP-Cy5.5, HLA-DR-APC; CD16/57-FITC, CD7-PE, CD4-PerCP-Cy5.5, CD3-PE-Cy7, CD56-APC, CD8-APC-H7, CD2-V450, CD45-V500; CD16-FITC, CD13-PE, CD45-PerCP-Cy5.5, CD11b-APC; CD36-FITC, CD64-PE, CD45-PerCP-Cy5, CD34-APC; cytoplasmic (c) TdT-FITC, cMPO-PE, cCD3-PerCP-Cy5.5, cCD34-APC; kappa-FITC, lambda-PE, CD19-PerCP-Cy5.5, CD5-APC; CD38-FITC, CD22-PE, CD20-PerCP-Cy5.5, CD10-APC. All of the antibodies were obtained from BD Biosciences (San Jose, CA). Files were acquired with BD FACS Canto II instruments and analyzed with DIVA software (Becton Dickinson, San Jose, CA).

DISCUSSION

  1. Top of page
  2. CASE HISTORY
  3. FLOW CYTOMETRIC STUDIES
  4. DISCUSSION
  5. LITERATURE CITED
  6. Supporting Information

Flow cytometric analysis performed on the aspirate specimen revealed a blastic neoplasm with the following phenotype: dim CD45 positive, CD34 negative, CD117 negative, CD4 positive, CD7 positive, CD56 positive, CD123 positive, TdT negative, MPO negative, CD3 negative (surface and cytoplasmic), CD19 negative, CD20 negative, CD61 negative, CD41 negative, CD13 negative, CD33 negative, partially CD36 positive, CD64 negative, CD14 negative (Figs. 2 and 3). Numerous blasts (88%) were noted on aspirate smears with minimal residual maturing hematopoietic elements (Fig. 1). Sheets of immature-appearing mononuclear cells were noted on marrow biopsy, and paraffin section immunohistochemical studies confirmed that the blasts were MPO negative, CD79a negative, CD3 negative, and strongly positive for CD123, CD4, and CD56. A butyrate esterase cytochemical stain performed on the aspirate smear did not provide evidence of monocytic differentiation. The overall features were considered diagnostic of blastic plasmacytoid dendritic cell neoplasm (BPDCN). The skin lesions were also biopsied and showed involvement by BPDCN.

image

Figure 2. Flow cytometric histograms detailing antigenic expression pattern of the dim CD45 positive blastic population (colored pink).

Download figure to PowerPoint

image

Figure 3. Flow cytometric histograms detailing antigenic expression pattern of the blastic population (colored red) as identified by light scatter characteristics.

Download figure to PowerPoint

BPDCN is the leukemic counterpart of plasmacytoid dendritic cells (PDC) ([1]). BPDCN is typically a disease of elderly patients, although a few pediatric cases have been reported ([2-4]). A subset of patients have a pre-existing myeloid neoplasm such as myelodysplasia, similar to this case ([4]). Cutaneous lesions are often present at the time of diagnosis, and isolated skin lesions may be the initial presenting feature. However, BPDCN widely disseminates, and despite an initial response to systemic chemotherapy, relapses are frequent in the absence of allogeneic hematopoietic stem cell transplantation (allo-SCT). Treatment with acute myeloid leukemia (AML)-type induction chemotherapy regimens followed by allo-SCT at the first complete remission has been advocated ([4, 5]). Although the older age of the patient populations presents a challenge to the treating hematologist/oncologist, reduced-intensity conditioning allo-SCT has been shown to be effective in patients up to 70 years of age ([6]).

However, the disease must first be correctly classified in order to enable appropriate therapy. Although BPDCN is a newly defined entity in the 2008 WHO classification, it is not a new disease, and previously had been known as “CD4+/CD56+ hematodermic neoplasm” as well as “blastic NK-cell lymphoma” ([4, 7-9]). Given that the neoplastic cells lack lineage-specific myeloid, B, or T-cell antigens, extensive immunophenotypic characterization must be employed to establish the diagnosis. The emergence of more specific PDC markers such as CD123 has made it possible to identify the PDC origin of BPDCN ([10]).

The primary differential diagnosis is with other types of precursor myeloid or lymphoid neoplasms, and familiarity with the immunophenotypic spectrum of BPDCN is essential. The neoplastic cells are typically dim CD45 positive and may be TdT positive, compatible with blastic, immature cells ([4, 10, 11]). Although TdT expression is more commonly seen in precursor lymphoid neoplasms, in contrast to lymphoblastic leukemias, BPDCN will not exhibit lineage-specific markers such as CD3, CD19, CD79a, or cytoplasmic CD22, although expression of the T-cell associated antigens CD2 and CD7 has been reported ([2]). Lack of CD3 and expression of CD56 may be seen in natural killer (NK) cell neoplasms; however, CD8 rather than CD4 is characteristic of NK cell neoplasms, which also typically have expression of the epsilon chain of CD3. Although BPDCN may show expression of the myeloid-associated antigen CD33, the lineage-specific marker myeloperoxidase (MPO) is negative, CD34 is not expressed, and CD117 positivity has only rarely been reported, in contrast to many AML ([2, 3]). The CD4+/CD56+ phenotype characteristic of BPDCN may overlap with monocytic AML, which can lack expression of CD34, CD117, and MPO ([12]). In addition, CD36 and CD68 expression may be seen in both BPDCN as well as monocytic AML. In difficult cases, cytochemical staining may be a useful diagnostic adjunct, as monocytic AML should exhibit positivity for non-specific esterase (NSE) whereas BPDCN is NSE negative. Given that a subset of BPDCN will lack expression of CD4 and/or CD56, utilizing PDC-specific markers is recommended in order to establish the diagnosis. CD123 is a robust PDC marker which has been extensively studied in prior flow cytometric studies, however, may also be seen in other hematologic malignancies such as AML, lymphoblastic leukemias, and hairy cell leukemias ([13, 14]). Additional immunohistochemical antibodies for use in tissue sections have become available to help identify PDC origin, including TCL1, BDCA-2, and CD2AP ([10, 15, 16]). These studies may be useful to correlate with the results of the flow cytometric analysis.

In summary, this case is an example of BPDCN, a rare but distinctive neoplasm with an aggressive clinical course. Familiarity with the immunophenotype (CD4+, CD56+, CD123+, occasionally TdT+, lack of lineage specific markers) enables distinction from other hematopoietic neoplasms with immunophenotypic overlap, which is essential for establishing the diagnosis and ensuring appropriate therapy.

CASE 5 DIAGNOSIS: Blastic Plasmacytoid Dendritic Cell Neoplasm

LITERATURE CITED

  1. Top of page
  2. CASE HISTORY
  3. FLOW CYTOMETRIC STUDIES
  4. DISCUSSION
  5. LITERATURE CITED
  6. Supporting Information
  • 1
    Chaperot L, Bendriss N, Manches O, Gressin R, Maynadie M, Trimoreau F, Orfeauvre H, Corront B, Feuillard J, Sotto JJ, Bensa JC, et al.Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 2001;97:32103217.
  • 2
    Jacob MC, Chaperot L, Mossuz P, Feuillard J, Valensi F, Leroux D, Bene MC, Bensa JC, Briere F, Plumas J.CD4+ CD56+ lineage negative malignancies: A new entity developed from malignant early plasmacytoid dendritic cells. Haematologica 2003;88:941955.
  • 3
    Jegalian AG, Buxbaum NP, Facchetti F, Feuillard J, Valensi F, Leroux D, Bene MC, Bensa JC, Briere F, Plumas J.Blastic plasmacytoid dendritic cell neoplasm in children: Diagnostic features and clinical implications. Haematologica 2010;95:18731879.
  • 4
    Feuillard J, Jacob MC, Valensi F, Maynadie M, Gressin R, Chaperot L, Arnoulet C, Brignole-Baudouin F, Drenou B, Duchayne E, et al.Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 2002;99:15561563.
  • 5
    Male HJ, Davis MB, McGuirk JP, Abhyankar S, Aljitawi OS, Zhang D, Ganguly S.Blastic plasmacytoid dendritic cell neoplasm should be treated with acute leukemia type induction chemotherapy and allogeneic stem cell transplantation in first remission. Int J Hematol 2010;92:398400.
  • 6
    Dietrich S, Andrulis M, Hegenbart U, Schmitt T, Bellos F, Martens UM, Meissner J, Kramer A, Ho AD, Dreger P.Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: Results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity. Biol Blood Marrow Transplant 2011;17:12501254.
  • 7
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues,4th ed. Lyon, France: IARC Press; 2008.
  • 8
    Weaver J, Hsi ED.CD4+/CD56+ hematodermic neoplasm (blastic NK-cell lymphoma). J Cutan Pathol2008;35:975977.
  • 9
    Herling M, Jones D. CD4+/CD56+ hematodermic tumor: The features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol 2007;127:687700.
  • 10
    Marafioti T, Paterson JC, Ballabio E, Reichard KK, Tedoldi S, Hollowood K, Dictor M, Hansmann ML, Pileri SA, Dyer MJ, et al.Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood2008;111:37783792.
  • 11
    Reichard KK, Burks EJ, Foucar MK, Wilson CS, Viswanatha DS, Hozier JC, Larson RS.CD4(+) CD56(+) lineage-negative malignancies are rare tumors of plasmacytoid dendritic cells. Am J Surg Pathol 2005;29:12741283.
  • 12
    Xu Y, McKenna RW, Wilson KS, Karandikar NJ, Schultz RA, Kroft SH. Immunophenotypic identification of acute myeloid leukemia with monocytic differentiation. Leukemia 2006;20:13211324.
  • 13
    Rollins-Raval MA, Roth CG. The value of immunohistochemistry for CD14, CD123, CD33, myeloperoxidase and CD68R in the diagnosis of acute and chronic myelomonocytic leukaemias. Histopathology 2012;60:933942.
  • 14
    Munoz L, Nomdedeu JF, Lopez O, Carnicer MJ, Bellido M, Aventin A, Brunet S, Sierra J.Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica 2001;86:12611269.
  • 15
    Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D.TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood2003;101:50075009.
  • 16
    Pilichowska ME, Fleming MD, Pinkus JL, Pinkus GS.CD4+/CD56+ hematodermic neoplasm (“blastic natural killer cell lymphoma”): Neoplastic cells express the immature dendritic cell marker BDCA-2 and produce interferon. Am J Clin Pathol 2007;128:445453.

Supporting Information

  1. Top of page
  2. CASE HISTORY
  3. FLOW CYTOMETRIC STUDIES
  4. DISCUSSION
  5. LITERATURE CITED
  6. Supporting Information

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
cytob21060-sup-0001-suppCase5Tube11761KSupporting Information
cytob21060-sup-0002-suppCase5Tube21761KSupporting Information
cytob21060-sup-0003-suppCase5Tube31761KSupporting Information
cytob21060-sup-0004-suppCase5Tube41761KSupporting Information
cytob21060-sup-0005-suppCase5Tube51761KSupporting Information
cytob21060-sup-0006-suppCase5Tube61761KSupporting Information
cytob21060-sup-0007-suppCase5Tube72933KSupporting Information
cytob21060-sup-0008-suppCase5Tube81761KSupporting Information
cytob21060-sup-0009-suppCase5Tube91761KSupporting Information

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.